Disease modifying trials in Alzheimer's disease: Perspectives for the future

Journal of Alzheimer's Disease

Volumn 15, Issue 2, 2008, Pages 289-301

  Vellas, Bruno ^a,b,c   Coley, Nicola ^b,d   Andrieu, Sandrine ^a,b  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c Serv Univ Psychiat l'Enfant l'A   (France)

^d UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Alzheimer's disease; Clinical trials; Dementia; Disease progression; Disease modifying treatment; Drug evaluation; Methodology; Outcomes; Prevention; Research design

Indexed keywords

AAB 002; ACC 001; ALPHA TOCOPHEROL; ALZHEIMER DISEASE VACCINE; ATORVASTATIN; AZD 103; BAPINEUZUMAB; CAD 106; CELECOXIB; DONEPEZIL; E 2012; ESTROGEN; FOLIC ACID; GAMMA SECRETASE INHIBITOR; GESTAGEN; GINKGO BILOBA EXTRACT; HOMOTAURINE; IMMUNOGLOBULIN; LY 2062430; MK 0249; MONOCLONAL ANTIBODY; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; NAPROXEN; PBT 2; PLACEBO; SIMVASTATIN; TARENFLURBIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN B GROUP; XALIPRODEN;

ALZHEIMER DISEASE; BRAIN ATROPHY; CLINICAL RESEARCH; CLINICAL TRIAL; DISEASE COURSE; DRUG SCREENING; HUMAN; METHODOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW;

EID: 54349126967     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2008-15212     Document Type: Review

References (60)

1. P.A. Aisen, S. Gauthier, B. Vellas, R. Briand, D. Saumier, J. Laurin and D. Garceau, Alzhemed: A Potential Treatment for Alzheimer's Disease, Curr Alzheimer Res 4 (2007), 473-478.
2. S. Andrieu, O. Rascol, T. Lang, H. Grandjean and B. Vellas, Disease modifying trials in Alzheimer disease: methodological and statistical issues, J Nutr Health Aging 10 (2006), 116-117.
3. Biomarkers Definitions Working Group, Biomarkers and surrogate endpoints: preferred definitions and conceptual framework, Clin Pharmacol Ther 69 (2001), 89-95.
4. K. Blennow and H. Hampel, CSF markers for incipient Alzheimer's disease, Lancet Neurol 2 (2003), 605-613.
5. J.C. Breitner, B.K. Martin and C.L. Meinert, The suspension of treatments in ADAPT: concerns beyond the cardiovascular safety of celecoxib or naproxen, PLoS Clin Trials 1 (2006), e41.
6. K. Buerger, S.J. Teipel, R. Zinkowski, K. Blennow, H. Arai, R. Engel, K. Hofmann-Kiefer, C. McCulloch, U. Ptok, R. Heun, N. Andreasen, J. DeBernardis, D. Kerkman, H. Moeller, P. Davies and H. Hampel, CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects, Neurology 59 (2002), 627-629.
7. K. Buerger, R. Zinkowski, S.J. Teipel, T. Tapiola, H. Arai, K. Blennow, N. Andreasen, K. Hofmann-Kiefer, J. DeBernardis, D. Kerkman, C. McCulloch, R. Kohnken, F. Padberg, T. Pirttila, M.B. Schapiro, S.I. Rapoport, H.J. Moller, P. Davies and H. Hampel, Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231, Arch Neurol 59 (2002), 1267-1272.
8. ClinicalTrials.gov, Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study, http://www.clinicaltrials.gov/ct2/show/ NCT00053599?term=NCT00053599&rank=1, Last updated February 19, 2008, Accessed on May 7, 2008.
9. ClinicalTrials.gov, DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease, http://www.clinicaltrials.gov/ ct2/show/NCT00440050?term=Docosahexaenoic+Acid+%28DHA%29+alzheimer&rank=1, Last updated on February 28, 2008, Accessed on May 7, 2008.
10. ClinicalTrials.gov, Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's, http://www.clinicaltrials.gov/ct2/show/NCT00105547?term= FLURIZAN&rank=3, Last updated December 11, 2007, Accessed May 7, 2008.
11. ClinicalTrials.gov, European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients, http://www.clinicaltrials.gov/ct2/show/ NCT00217763?term=NCT00217763&rank=1, Last updated on September 7, 2007, Accessed on May 7, 2008.
12. ClinicalTrials.gov, Evaluation of 3APS in Patients With Mild to Moderate Alzheimer's Disease, http://www.clinicaltrials.gov/ct2/show/NCT00088673?term= NCT00088673&rank=1, Last updated on February 27, 2007, Accessed on May 7, 2008.
13. ClinicalTrials.gov, Global Efficacy Study of MPC-7869 to Treat PatientsWith Alzheimer's, http://www.clinicaltrials.gov/ct2/show/NCT00322036? term=FLURIZAN&rank=2, Last updated December 11, 2007, Accessed on May 7, 2008.
14. ClinicalTrials.gov, Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type, http://www.clinicaltrials. gov/ct2/show/NCT00104013?term=NCT00104013&rank=1, Last updated on August 2, 2007, Accessed on May 7, 2008.
15. ClinicalTrials.gov, VITAL - VITamins to Slow ALzheimer's Disease (Homocysteine Study), http://www.clinicaltrials.gov/ct2/show/NCT00056225?term= NCT00056225&rank=1, Last updated on March 14, 2007, Accessed on May 7, 2008.
16. J. Cummings, Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials, Alzheimers Dementia 2 (2006), 263-271.
17. J.L. Cummings, M. Mega, K. Gray, S. Rosenberg-Thompson, D.A. Carusi and J. Gornbein, The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia, Neurology 44 (1994), 2308-2314.
18. J.F. Dartigues, C. Fabrigoule, L. Letenneur, H. Amieva, F. Thiessard and J.M. Orgogozo, Epidemiology of memory disorders, Therapie 52 (1997), 503-506.
19. S.T. DeKosky, A. Fitzpatrick, D.G. Ives, J. Saxton, J. Williamson, O.L. Lopez, G. Burke, L. Fried, L.H. Kuller, J. Robbins, R. Tracy, N. Woolard, L. Dunn, R. Kronmal, R. Nahin and C. Furberg, The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia, Contemp Clin Trials 27 (2006), 238-253.
20. B. Dubois, H.H. Feldman, C. Jacova, S.T. Dekosky, P. Barberger-Gateau, J. Cummings, A. Delacourte, D. Galasko, S. Gauthier, G. Jicha, K. Meguro, J. O'Brien, F. Pasquier, P. Robert, M. Rossor, S. Salloway, Y. Stern, P.J. Visser and P. Scheltens, Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria, Lancet Neurol 6 (2007), 734-746.
21. J. Durga, M.P. Van Boxtel, E.G. Schouten, F.J. Kok, J. Jolles, M.B. Katan and P. Verhoef, What can we learn from the FACIT trial: a randomized, double blind, controlled trial, J Nutr Health Aging 11 (2007), 320-324.
22. J. Durga, M.P. van Boxtel, E.G. Schouten, F.J. Kok, J. Jolles, M.B. Katan and P. Verhoef, Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial, Lancet 369 (2007), 208-216.
23. H. Feldman, D. Sparks, R. Doody, M. Kivipelto, R. Jones, M. Sovel, A. Breazna, J. Hey-Hadavi and T.H.E. LEAD-e Investigators, Design and baseline data for a study of lipitor's effect in Alzheimer's dementia, 8th International Conference on AD/PD 2007, Salzburg, Austria, http://www.kenes.com/adpd2007/ program/session1.asp?SessionId=PO2N&SSessionDate=3/16/2007, Accessed on May 7, 2008.
24. H.H. Feldman, S. Ferris, B. Winblad, N. Sfikas, L. Mancione, Y. He, S. Tekin, A. Burns, J. Cummings, T. del Ser, D. Inzitari, J.M. Orgogozo, H. Sauer, P. Scheltens, E. Scarpini, N. Herrmann, M. Farlow, S. Potkin, H.C. Charles, N.C. Fox and R. Lane, Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study, Lancet Neurol 6 (2007), 501-512.
25. A.S. Fleisher, R. Raman, E.R. Siemers, B.B. Sowell, L.M. Becerra, C.M. Clark, M.R. Farlow, J.E. Galvin, E.R. Pesking, J.F. Quinn, D. Sherzai, P.A. Aisen and L.J. Thal, Phase II trial with a gamma-secretase inhibitor in mild-to-moderate Alzheimer's disease Alzheimer's Disease Prevention Meeting, Washington, D.C. (June 11, 2007), Abstract HT-005.
26. M.F. Folstein, S.E. Folstein and P.R. McHugh, "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res 12 (1975), 189-198.
27. N.C. Fox, R.S. Black, S. Gilman, M.N. Rossor, S.G. Griffith, L. Jenkins and M. Koller, Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease, Neurology 64 (2005), 1563-1572.
28. D. Galasko, D. Bennett, M. Sano, C. Ernesto, R. Thomas, M. Grundman and S. Ferris, An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study, Alzheimer Dis Assoc Disord 11 Suppl 2 (1997), S33-S39.
29. V. Gardette, N. Coley, O. Toulza and S. Andrieu, Attrition in geriatric research: how important is it and how should it be dealt with?, J Nutr Health Aging 11 (2007), 265-271.
30. M.I. Geerlings, C. Jonker, L.M. Bouter, H.J. Ader and B. Schmand, Association between memory complaints and incident Alzheimer's disease in elderly people with normal baseline cognition, Am J Psychiatry 156 (1999), 531-537.
31. S. Gilman, M. Koller, R.S. Black, L. Jenkins, S.G. Griffith, N.C. Fox, L. Eisner, L. Kirby, M.B. Rovira, F. Forette and J.M. Orgogozo, Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial, Neurology 64 (2005), 1553-1562.
32. R.C. Green and S.T. DeKosky, Primary prevention trials in Alzheimer disease, Neurology 67 (2006), S2-S5.
33. Adapt Research Group, C.G. Lyketsos, J.C. Breitner, R.C. Green, B.K. Martin, C. Meinert, S. Piantadosi and M. Sabbagh, Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial, Neurology 68 (2007), 1800-1808.
34. J. Harrison, S.L. Minassian, L. Jenkins, R.S. Black, M. Koller and M. Grundman, A neuropsychological test battery for use in Alzheimer disease clinical trials, Arch Neurol 64 (2007), 1323-1329.
35. J.E. Harrison, Measuring Cognitive Change in Alzheimer's Disease Clinical Drug Trials., J Nutr Health Aging 11 (2007), 327-329.
36. S. Hendrix, S. Horton and J.M. Orgogozo, Modification of the randomized-withdrawal and staggered start clinical trial designs: Toward a practical demonstration of disease modification in Alzheimer's disease, European Federation of Neurological Societies (EFNS), Brussels, Belgium (August 25-28, 2007), P1080.
37. J.H. Kang, N. Cook, J. Manson, J.E. Buring and F. Grodstein, Arandomized trial of vitaminEsupplementation and cognitive function in women, Arch Intern Med 166 (2006), 2462-2468.
38. J.H. Kang, N. Cook, J. Manson, J.E. Buring and F. Grodstein, Low dose aspirin and cognitive function in the women's health study cognitive cohort, BMJ 334 (2007), 987.
39. P. Leber, Slowing the progression of Alzheimer disease: methodologic issues, Alzheimer Dis Assoc Disord 11(5) (1997), S10-S21; discussion S37-S19.
40. S. Lovestone, Biomarkers in Alzheimer's disease, J Nutr Health Aging 10 (2006), 118-122.
41. J.A. McMahon, T.J. Green, C.M. Skeaff, R.G. Knight, J.I. Mann and S.M. Williams, A controlled trial of homocysteine lowering and cognitive performance, NEngl J Med 354 (2006), 2764-2772.
42. J.C. Morris, The Clinical Dementia Rating (CDR): current version and scoring rules, Neurology 43 (1993), 2412-2414.
43. S.E. Nissen, ADAPT: the wrong way to stop a clinical trial, PLoS Clin Trials 1 (2006), e35.
44. L. Parnetti, A. Lanari, S. Amici, V. Gallai, E. Vanmechelen and F. Hulstaert, CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group, Neurol Sci 22 (2001), 77-78.
45. E. Reynish, F. Cortes, S. Andrieu, C. Cantet, M. Olde Rikkert, R. Melis, L. Froelich, G.B. Frisoni, L. Jonsson, P.J. Visser, P.J. Ousset and B. Vellas, The ICTUS Study: A Prospective longitudinal observational study of 1,380 AD patients in Europe. Study design and baseline characteristics of the cohort, Neuroepidemiology 29 (2007), 29-38.
46. W.G. Rosen, R.C. Mohs and K.L. Davis, A new rating scale for Alzheimer's disease, Am J Psychiatry 141 (1984), 1356-1364.
47. C. Sampaio, Alzheimer disease: disease modifying trials; where are we? Where do we need to go? A reflective paper, J Nutr Health Aging 10 (2006), 113-115.
48. A.J. Saykin, H.A. Wishart, L.A. Rabin, R.B. Santulli, L.A. Flashman, J.D. West, T.L. McHugh and A.C. Mamourian, Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI, Neurology 67 (2006), 834-842.
49. S.A. Shumaker, C. Legault, S.R. Rapp, L. Thal, R.B. Wallace, J.K. Ockene, S.L. Hendrix, B.N. Jones, 3rd, A.R. Assaf, R.D. Jackson, J.M. Kotchen, S. Wassertheil-Smoller and J. Wactawski-Wende, Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial, JAMA 289 (2003), 2651-2662.
50. S.A. Shumaker, C. Legault, L. Kuller, S.R. Rapp, L. Thal, D.S. Lane, H. Fillit, M.L. Stefanick, S.L. Hendrix, C.E. Lewis, K. Masaki and L.H. Coker, Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study, JAMA 291 (2004), 2947-2958.
51. E.R. Siemers, C. Benson, C. Gonzales, R. Hansen, R.A. Dean, M.R. Farlow and D. R., Safety assessments and biomarker changes following a monoclonal Ab antibody given to subjects with Alzheimer's disease, Alzheimers Dementia 2 (2006), S80.
52. D.H. Silverman, S.S. Gambhir, H.W. Huang, J. Schwimmer, S. Kim, G.W. Small, J. Chodosh, J. Czernin and M.E. Phelps, Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits, J Nucl Med 43 (2002), 253-266.
53. L.J. Thal, S.H. Ferris, L. Kirby, G.A. Block, C.R. Lines, E. Yuen, C. Assaid, M.L. Nessly, B.A. Norman, C.C. Baranak and S.A. Reines, A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment, Neuropsychopharmacology 30 (2005), 1204-1215.
54. B. Vellas, S. Andrieu, P.J. Ousset, M. Ouzid and H. Mathiex-Fortunet, The GuidAge study: methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761 for prevention of Alzheimer disease in patients over 70 with a memory complaint, Neurology 67 (2006), S6-S11.
55. B. Vellas, S. Andrieu, C. Sampaio and G. Wilcock, Disease-modifying trials in Alzheimer's disease: a European task force consensus, Lancet Neurol 6 (2007), 56-62.
56. B. Vellas, S. Andrieu, C. Sampaio, N. Coley and G. Wilcock, Endpoints for Trials in Alzheimer's Disease: a European Task Force Consensus, Lancet Neurol 7 (2008), 436-450.
57. P.J. Visser, P. Scheltens and F.R. Verhey, Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?, J Neurol Neurosurg Psychiatry 76 (2005), 1348-1354.
58. G.K. Wilcock, S.E. Black, S. Hendrix, K. Zavitz, M. Laughlin and E. Swabb, Efficacy and safety of tarenflurbil (Flurizan), a selective Aβ42-lowering agent, in Alzheimer's disease: A Phase 2 trial of up to 24 months of treatment, European Federation of Neurological Societies (EFNS), Brussels, Belgium (August 25-28, 2007), SC306.
59. A. Wimo, A.L. Wetterhold, V. Master and B. Winblad, Evaluation of healthcare resource utilization and caregiver time in anti-dementia drug trials. A quantitative assessment battery, in: The Health Economics of Dementia, A. Wimo, B. Jonsson, G. Karlsson and B. Winblad, eds, John Wiley and Sons, London, 1998, pp. 465-499.
60. S.H. Zarit, K.E. Reever and J. Bach-Peterson, Relatives of the impaired elderly: correlates of feelings of burden, Gerontologist 20 (1980), 649-655.